Dacomitinib PF-00299804 vs Pyrotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline

Dacomitinib PF-00299804

Rights held by Pfizer; US product discontinued

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01774721 · Phase 3 · completed

The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.

Next expected readout: April 2027 · NCT04946968 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11) (met)

Result source: NCT01774721

Pyrotinib

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04447118 · Phase 3 · completed

The study randomly assigned 151 participants to pyrotinib or active treatment with docetaxel, with the primary endpoint assessed by an independent committee blinded to treatment assignment. Because results for the progression-free survival comparison have not been posted, the trial provides limited evidence at this time despite its randomized design.

Next expected readout: December 2026 · NCT05482568 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDacomitinib PF-00299804Pyrotinib
PFS, median14.7 vs 9.2vs Gefitinibn 227NCT01774721
11 other results
—Not posted · NCT04447118
OS, median6.8 vs 6.3+0.5 vs placebon 480NCT01000025
8 other results
—Not posted · NCT04447118
ORR7.1% vs 1.3%+5.8 vs placebon 480NCT01000025
5 other results
—Not posted · NCT04447118
Duration of response, median9.2 vs 10.1vs Erlotinibn 52NCT01360554
8 other results
—Not posted · NCT04447118

PFS, median

Dacomitinib PF-00299804
14.7 vs 9.2vs Gefitinibn 227NCT01774721
11 other results
Pyrotinib
—Not posted · NCT04447118

OS, median

Dacomitinib PF-00299804
6.8 vs 6.3+0.5 vs placebon 480NCT01000025
8 other results
Pyrotinib
—Not posted · NCT04447118

ORR

Dacomitinib PF-00299804
7.1% vs 1.3%+5.8 vs placebon 480NCT01000025
5 other results
Pyrotinib
—Not posted · NCT04447118

Duration of response, median

Dacomitinib PF-00299804
9.2 vs 10.1vs Erlotinibn 52NCT01360554
8 other results
Pyrotinib
—Not posted · NCT04447118
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Pyrotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dacomitinib PF-00299804: 4 of 4 rows · Pyrotinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDacomitinib PF-00299804
Dropout rate
n/a: no completion milestonea
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
n/a: no completion milestone
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
79.2%
NCT04511533 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT02382796 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
50%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
36.4%45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
0%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
43.3%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
48%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneDacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneDacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT00769067 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
—
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—
NCT04511533 · Phase 4 · registry result, not featured evidence
—
NCT02382796 · Phase 2 · registry result, not featured evidence
18.8%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
4%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
0%Dacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
3.3%Dacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
—
NCT00769067 · Phase 2 · registry result, not featured evidence
—PF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
—PF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Serious AEs
30.4%a
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
40.8%
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
40%
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.8%
NCT04511533 · Phase 4 · registry result, not featured evidence
28.6%
NCT02382796 · Phase 2 · registry result, not featured evidence
43.8%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
36.4%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
37.9%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
40.9%45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
42.9%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
32.8%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
24%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
32.6%Dacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
30%Dacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
36.6%
NCT00769067 · Phase 2 · registry result, not featured evidence
18%PF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
37.5%PF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 87.7%
paronychia 61.7%
dermatitis acneiform 49.3%
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
diarrhoea 73.9%
rash 50%
decreased appetite 31.7%
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
diarrhea 79.7% (placebo 19.7%)
rash acneiform 59.3% (placebo 10%)
dyspnea 57.9% (placebo 55.2%)
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
diarrhoea 51.5%
rash 42.6%
weight decreased 34.7%
NCT04511533 · Phase 4 · registry result, not featured evidence
contusion 28.6%
diarrhoea 28.6%
dry skin 28.6%
NCT02382796 · Phase 2 · registry result, not featured evidence
45/60 mg
diarrhoea 87.5%
rash 50%
dry skin 43.8%
NCT01858389 · Phase 2 · registry result, not featured evidence
45/60 mg
diarrhoea 72.7%
rash 54.5%
nausea 40.9%
NCT01858389 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 81.8%
nausea 42.4%
rash 42.4%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg + 100 mg
diarrhoea 78.8%
nausea 47%
rash 43.9%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 100%
rash 71.4%
chills 57.1%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 80.6%
decreased appetite 37.3%
rash 37.3%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 92%
dermatitis acneiform 72%
pruritus 68%
NCT01465802 · Phase 2 · registry result, not featured evidence
diarrhoea 95.5%
dermatitis acneiform 76.4%
dry skin 43.8%
NCT00818441 · Phase 2 · registry result, not featured evidence
diarrhoea 93.3%
dermatitis acneiform 73.3%
fatigue 56.7%
NCT00818441 · Phase 2 · registry result, not featured evidence
diarrhoea 72%
dermatitis acneiform 64.5%
decreased appetite 29%
NCT00769067 · Phase 2 · registry result, not featured evidence
diarrhoea 88%
dermatitis acneiform 66%
fatigue 62%
NCT00548093 · Phase 2 · registry result, not featured evidence
diarrhoea 81.3%
dermatitis acneiform 75%
dry skin 43.8%
NCT00548093 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dacomitinib PF-00299804

PFS 14.7 vs 9.2 Gefitinib months
time to event · months
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 7 more results
16.6 vs 11 Gefitinib months
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.6 vs 2.5 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
2.6 vs 2.5 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
1.9 vs 1.9 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
1.9 vs 1.9 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
2.66 vs 1.58 placebo months
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.86 vs 1.92 Erlotinib months*
NCT00769067 · Phase 2 · registry result, not featured evidence · converted to months from 12.4 weeks as posted
Overall Survival 34.1 vs 27 Gefitinib months
time to event · months
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 6 more results
7.9 vs 8.3 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
8.1 vs 8.5 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
6.83 vs 6.31 placebo months
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7 vs 5.19 placebo months
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.23 vs 7.52 placebo months
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.55 vs 7.45 Erlotinib months*
NCT00769067 · Phase 2 · registry result, not featured evidence · converted to months from 41.4 weeks as posted
Overall Survival 56.4 vs 45.7 Gefitinib probability of survival @ 130wk
absolute value · probability of survival
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Stable Disease 13.2% (n=227) vs 12% (n=225) Gefitinib
event count · % of participants
Stable disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 30 Participants as posted
show 1 more result
16.7% (n=227) vs 21.8% (n=225) Gefitinib*
Stable disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 38 Participants as posted
Progressive Disease 5.3% (n=227) vs 6.7% (n=225) Gefitinib
event count · % of participants
Progressive disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 12 Participants as posted
show 1 more result
4% (n=227) vs 4.9% (n=225) Gefitinib*
Progressive disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 9 Participants as posted
Duration of Response 14.8 vs 8.3 Gefitinib months
time to event · months
DoR: IRC review
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 74.9% (n=227) vs 71.6% (n=225) Gefitinib
responder rate · % of participants
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
75.3% (n=227) vs 70.2% (n=225) Gefitinib
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.1% (n=480) vs 1.3% (n=240) placebo
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17% (n=94) vs 5.3% (n=94) Erlotinib
NCT00769067 · Phase 2 · registry result, not featured evidence
Duration of Response 9.2 vs 10.1 Erlotinib months
time to event · months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 2 more results
10.4 vs 9.2 Erlotinib months
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.59 vs 9.25 Erlotinib months*
NCT00769067 · Phase 2 · registry result, not featured evidence · converted to months from 71.9 weeks as posted
ORR 6.3% (n=16)45/60 mg
responder rate · % of participants
No placebo or comparator arm
NCT01858389 · Phase 2 · registry result, not featured evidence
show 1 more result
50.5% (n=101)
NCT04511533 · Phase 4 · registry result, not featured evidence
Duration of Response 2.83 months45/60 mg
time to event · months
No placebo or comparator arm
NCT01858389 · Phase 2 · registry result, not featured evidence
show 5 more results
11.1 months
NCT04511533 · Phase 4 · registry result, not featured evidence
12.9 months
NCT00818441 · Phase 2 · registry result, not featured evidence
12.4 months
NCT00818441 · Phase 2 · registry result, not featured evidence
10.43 months*
NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 45.2 weeks as posted
2.79 months*
NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 12.1 weeks as posted
Complete 0% (n=16)45/60 mg
responder rate · % of participants
No placebo or comparator arm
Complete response (CR)
NCT01858389 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Partial 6.3% (n=16)45/60 mg
responder rate · % of participants
No placebo or comparator arm
Partial response (PR)
NCT01858389 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted

+ 25 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dacomitinib PF-00299804's landscape · Pyrotinib's landscape